Trial
NCT04860258
COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
CureVac
Collaborators
—
Condition
Coronavirus
Intervention
CVnCoV Vaccine
Why stopped
The Principal Investigators and CureVac decided to terminate the trial early following a change to the risk/benefit profile.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-05-13